

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**Shanghai Henlius Biotech, Inc.**

**上海復宏漢霖生物技術股份有限公司**

*(A joint stock company incorporated in the People's Republic of China with limited liability)*

**(Stock code: 2696)**

## **CHANGE OF DATE OF BOARD MEETING**

Reference is made to the announcement of Shanghai Henlius Biotech, Inc. (the “**Company**”) dated 15 March 2023 in relation to the proposed meeting of the board of directors (the “**Board**”) of the Company to be held on Sunday, 26 March 2023 for the purpose of considering and approving the final results of the Company and its subsidiaries for the year ended 31 December 2022 and the recommendation of a final dividend, if any, and transacting any other business.

The Board hereby announces that, as additional time is required for the Company's auditor to complete its audit procedures, the meeting of the Board has been changed to Friday, 31 March 2023 to consider the above matters.

On behalf of the Board  
**Shanghai Henlius Biotech, Inc.**  
**Wenjie Zhang**  
*Chairman*

Hong Kong, 24 March 2023

*As at the date of this announcement, the board of directors of the Company comprises Mr. Wenjie Zhang as the chairman and executive director, Mr. Qiyu Chen, Mr. Yifang Wu, Ms. Xiaohui Guan, Mr. Deyong Wen and Mr. Zihou Yan as the non-executive directors, and Mr. Tak Young So, Dr. Lik Yuen Chan, Dr. Guoping Zhao and Dr. Ruilin Song as the independent non-executive directors.*